G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023
18 Oktober 2023 - 1:30PM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, will host a webcast and conference call to provide a
financial and corporate update for the third quarter 2023 on
Wednesday November 1, 2023, at 8:30 a.m. ET.
Please note that there is a new process to access the call via
telephone. To register and receive a dial in number and unique PIN
to access the live conference call, please follow this link to
register online. While not required, it is recommended that you
join 10 minutes prior to the start of the event. A live and
archived webcast will be available on the Events &
Presentations page of the company’s website:
www.g1therapeutics.com. The webcast will be archived on the same
page for 90 days following the event.
About G1 TherapeuticsG1 Therapeutics, Inc. is a
commercial-stage biopharmaceutical company focused on the
development and commercialization of next generation therapies that
improve the lives of those affected by cancer, including the
Company’s first commercial product, COSELA® (trilaciclib). G1 has a
deep clinical pipeline and is executing a development plan
evaluating trilaciclib in a variety of solid tumors, including
breast, lung, and bladder cancers. G1 Therapeutics is based in
Research Triangle Park, N.C. For additional information, please
visit www.g1therapeutics.com and follow us on X (formerly known as
Twitter) @G1Therapeutics and LinkedIn.
G1 Therapeutics® and the G1 Therapeutics logo and
COSELA® and the COSELA logo are trademarks of G1
Therapeutics, Inc.
G1 Therapeutics Contacts:
Will RobertsCommunications OfficerVice President, Investor
Relations and Corporate Communications(919) 907-1944
wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024